2023 Early Hearing Detection & Intervention Conference
March 5-7, 2023 • Cincinnati, OH
10/26/2019 | 3:45 PM - 5:00 PM | The Cost-Effectiveness of School Hearing Screening Programs: a Scoping Review | Ventana Ballroom C
The Cost-Effectiveness of School Hearing Screening Programs: a Scoping Review
Background
School hearing screening can improve access to care for children who suffer from childhood hearing loss that is not detected on or develops after initial newborn hearing screening. However, implementation of school hearing screening around the world is sporadic, and cost effectiveness is not well understood.
Objectives
This scoping review was conducted to summarize all published cost-effectiveness studies on school hearing screening programs globally.
Eligibility criteria
Studies that included a cost analysis of screening programs for school-aged children in the school environment were eligible for inclusion.
Search strategy
A structured search algorithm was applied to four databases: Pubmed (Medline), Embase, CINAHL, and Cochrane Library. The search was run independently by two study authors.
Extraction of results
Results were reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and The Joanna Briggs Institute (JBI) methodology for scoping reviews. Data extracted included differences in study design, screening methodology, costs, utilities, and incremental cost-effectiveness ratios.
Results
Four of the five studies that conducted a cost-effectiveness analysis reported that school hearing screening was cost-effective through the calculation of incremental cost-effectiveness ratios (ICERs). One study reported that a new school hearing screening was cost-effective while being cheaper and more effective than the existing program, two studies reported that school hearing screening was cost-effective with ICERs ranging from $1,079 to $4,304 International Dollars (Int$), and one study reported school hearing screening was cost-effective with an ICER of £2,445. One study reported that school-entry hearing screening was not cost-effective when compared with no screening, being more expensive and less effective.
Conclusions
The majority of studies concluded that school hearing screening was cost-effective. However, significant differences in methodology and region-specific estimates of model inputs limit the generalizability of these findings.
- Understand the current evidence regarding cost-effectiveness of school hearing screening programs globally
- Examine the reasons why cost-effectiveness estimates might vary between regions and study groups
- Identify specific areas needing more research in order to develop more accurate cost-effectiveness analyses of school hearing screening programs
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Michael Yong
(), University of British Columbia, mjcyong@gmail.com;
Michael Yong is a Resident Physician (Post-Graduate Year 4) in the Division of Otolaryngology – Head and Neck Surgery at the University of British Columbia. Under the support of the two-year Clinician Investigator Program research fellowship award from the University of British Columbia, he is currently studying at Johns Hopkins University as an MBA candidate with the Carey School of Business and an MPH candidate with the Bloomberg School of Public Health. His interests lie at the intersection of medicine, technology, business, and public health, where he is most drawn to addressing issues with healthcare efficiency using disruptive innovation. He is currently a research fellow working on a cost-effectiveness model of a hearing intervention in rural Alaska under Dr. Susan Emmett from Duke University, and a research fellow studying international hearing aid access at the Cochlear Centre of Aging and Hearing under Dr. Frank Lin at Johns Hopkins.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Jiahe Liang
(), Johns Hopkins University, jiahe.liang@jhu.edu ;
.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Jeromie Ballreich
(), Johns Hopkins University, jballre2@jhu.edu;
Dr. Ballreich is a health economist specializing in three main areas: pharmaceutical economics and policy; economic evaluations alongside clinical studies; and high-cost/high-needs patient populations with a focus on trauma. Dr. Ballreich has gained expertise in these areas by working alongside eminent faculty at Johns Hopkins University during his education and as a junior faculty. His peer-reviewed work has been published in New England Journal of Medicine, American Journal of Managed Care, and other academic journals. He has been an invited workshop participant and presenter at the National Academy of Medicine, International Society of Pharmacoeconmics and Outcomes Research annual meeting, and other professional societies.
His work is currently split between the Major Extremity Trauma Research Consortium (METRC), the Johns Hopkins Drug Access and Affordability Initiative (JHDAAI), and the directorship of the Masters in Health Economics and Outcomes Research program at Johns Hopkins Bloomberg School of Public Health.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Brian Westerberg
(), University of British Columbia, BWesterberg@providencehealth.bc.ca ;
Dr. Westerberg graduated from Queen’s University Faculty of Medicine in 1989. He then completed two years of Residency training in General Surgery before transferring to Vancouver to complete further training in Otolaryngology at the University of British Columbia. After completing a Fellowship in Otology & Neurotology at the California Ear Institute at Stanford University during 1995-96, Dr. Westerberg returned to the University of British Columbia. He subsequently completed a Masters in Health Care and Epidemiology at UBC in May 1999.
In addition to a busy clinical practice, Dr. Westerberg contributes to the teaching of medical students and residents, and offers a fellowship in Otology & Neurotology. He is currently Clinical Professor in the Department of Surgery with the University of British Columbia.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Jane Lea
(), University of British Columbia, JLea@providencehealth.bc.ca ;
Dr. Lea completed her undergraduate BSc degree in 1999 at The George Washington University (Washington DC), followed by her MD in 2005 from the Faculty of Medicine at The University of Toronto. She then completed a 5-year residency in Otolaryngology – Head & Neck Surgery at the University of Toronto in 2010. This was followed by subspecialty fellowship training in Otology/Neurotology at The University of British Columbia (2010-2011), and further complemented by training abroad at Johns Hopkins (Baltimore, USA) & Royal Prince Alfred Hospital (Sydney, Australia), with a special focus on disorders of the vestibular system (2011). In 2012, a second subspecialty fellowship was completed in Paediatric Otolaryngology at the University of British Columbia. Her current clinical practice focuses on disorders of the ear and its related nervous system, both in the adult and paediatric population.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Susan D. Emmett
(), Duke University School of Medicine Center for Health Policy and Inequalities Research, susan.emmett@duke.edu;
tba
ASHA DISCLOSURE:
Financial -
Nonfinancial -